The Diagnostic Accuracy of Claudin-4 Immunochemistry in Differentiating Metastatic Carcinomas From Mesothelial Processes in Serous Effusion Cytology: A Systematic Review and Meta-analysis
Distinguishing metastatic carcinomas from mesotheliomas or reactive mesothelial cells in pleural, peritoneal, and pericardial effusions is a common diagnostic problem cytopathologists encounter. To perform the first meta-analysis on the pooled diagnostic accuracy of claudin-4 immunochemistry in sero...
Saved in:
Published in | Archives of pathology & laboratory medicine (1976) |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
14.06.2024
|
Online Access | Get full text |
Cover
Loading…
Abstract | Distinguishing metastatic carcinomas from mesotheliomas or reactive mesothelial cells in pleural, peritoneal, and pericardial effusions is a common diagnostic problem cytopathologists encounter.
To perform the first meta-analysis on the pooled diagnostic accuracy of claudin-4 immunochemistry in serous effusion cytopathology.
This report followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for diagnostic test accuracy studies. Three databases (PubMed, Scopus, and the Cochrane Library) were searched until October 9, 2023, followed by study selection using specific inclusion and exclusion criteria and data extraction. The study quality assessment was performed by using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Statistical analysis was performed by using R to calculate the pooled sensitivity and specificity of claudin-4 immunochemistry. In addition, the diagnostic odds ratio was measured, representing the odds ratio of a positive result indicating a carcinoma rather than a mesothelial process in serous effusion cytology.
Fourteen observational studies, published between 2011 and 2023, fulfilled the selection criteria and were included. All 14 studies used the 3E2C1 clone. Claudin-4 immunochemistry showed a high diagnostic accuracy in serous effusion cytology. The pooled sensitivity and specificity were 98.02% (95% CI, 93.96%-99.37%) and 99.72% (95% CI, 97.36%-99.97%), respectively. Lastly, the pooled diagnostic odds ratio was 1660.5 (95% CI, 760.0-3627.8) and no evidence of statistical heterogeneity between the included studies was found (I2 = 0%, τ2 = 0).
Claudin-4 may be used as a single pan-carcinoma immunochemical biomarker in the differential diagnosis between metastatic carcinomas and mesotheliomas or reactive mesothelial cells in serous effusion cytology. |
---|---|
AbstractList | CONTEXT.—Distinguishing metastatic carcinomas from mesotheliomas or reactive mesothelial cells in pleural, peritoneal, and pericardial effusions is a common diagnostic problem cytopathologists encounter.OBJECTIVE.—To perform the first meta-analysis on the pooled diagnostic accuracy of claudin-4 immunochemistry in serous effusion cytopathology.DESIGN.—This report followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for diagnostic test accuracy studies. Three databases (PubMed, Scopus, and the Cochrane Library) were searched until October 9, 2023, followed by study selection using specific inclusion and exclusion criteria and data extraction. The study quality assessment was performed by using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Statistical analysis was performed by using R to calculate the pooled sensitivity and specificity of claudin-4 immunochemistry. In addition, the diagnostic odds ratio was measured, representing the odds ratio of a positive result indicating a carcinoma rather than a mesothelial process in serous effusion cytology.RESULTS.—Fourteen observational studies, published between 2011 and 2023, fulfilled the selection criteria and were included. All 14 studies used the 3E2C1 clone. Claudin-4 immunochemistry showed a high diagnostic accuracy in serous effusion cytology. The pooled sensitivity and specificity were 98.02% (95% CI, 93.96%-99.37%) and 99.72% (95% CI, 97.36%-99.97%), respectively. Lastly, the pooled diagnostic odds ratio was 1660.5 (95% CI, 760.0-3627.8) and no evidence of statistical heterogeneity between the included studies was found (I2 = 0%, τ2 = 0).CONCLUSIONS.—Claudin-4 may be used as a single pan-carcinoma immunochemical biomarker in the differential diagnosis between metastatic carcinomas and mesotheliomas or reactive mesothelial cells in serous effusion cytology. Distinguishing metastatic carcinomas from mesotheliomas or reactive mesothelial cells in pleural, peritoneal, and pericardial effusions is a common diagnostic problem cytopathologists encounter. To perform the first meta-analysis on the pooled diagnostic accuracy of claudin-4 immunochemistry in serous effusion cytopathology. This report followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for diagnostic test accuracy studies. Three databases (PubMed, Scopus, and the Cochrane Library) were searched until October 9, 2023, followed by study selection using specific inclusion and exclusion criteria and data extraction. The study quality assessment was performed by using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Statistical analysis was performed by using R to calculate the pooled sensitivity and specificity of claudin-4 immunochemistry. In addition, the diagnostic odds ratio was measured, representing the odds ratio of a positive result indicating a carcinoma rather than a mesothelial process in serous effusion cytology. Fourteen observational studies, published between 2011 and 2023, fulfilled the selection criteria and were included. All 14 studies used the 3E2C1 clone. Claudin-4 immunochemistry showed a high diagnostic accuracy in serous effusion cytology. The pooled sensitivity and specificity were 98.02% (95% CI, 93.96%-99.37%) and 99.72% (95% CI, 97.36%-99.97%), respectively. Lastly, the pooled diagnostic odds ratio was 1660.5 (95% CI, 760.0-3627.8) and no evidence of statistical heterogeneity between the included studies was found (I2 = 0%, τ2 = 0). Claudin-4 may be used as a single pan-carcinoma immunochemical biomarker in the differential diagnosis between metastatic carcinomas and mesotheliomas or reactive mesothelial cells in serous effusion cytology. |
Author | Ryu, Han Suk Kleinaki, Maria Arnaouti, Maria Nikas, Ilias P Vey, Johannes A Awounvo, Sinclair Ishak, Angela |
Author_xml | – sequence: 1 givenname: Maria surname: Kleinaki fullname: Kleinaki, Maria organization: From School of Medicine, European University Cyprus, Nicosia, Cyprus (Kleinaki, Ishak, Arnaouti, Nikas) – sequence: 2 givenname: Johannes A surname: Vey fullname: Vey, Johannes A organization: Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany (Vey, Awounvo) – sequence: 3 givenname: Sinclair surname: Awounvo fullname: Awounvo, Sinclair organization: Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany (Vey, Awounvo) – sequence: 4 givenname: Angela surname: Ishak fullname: Ishak, Angela organization: the Department of Internal Medicine, Henry Ford Health System, Detroit, Michigan (Ishak) – sequence: 5 givenname: Maria surname: Arnaouti fullname: Arnaouti, Maria organization: From School of Medicine, European University Cyprus, Nicosia, Cyprus (Kleinaki, Ishak, Arnaouti, Nikas) – sequence: 6 givenname: Han Suk surname: Ryu fullname: Ryu, Han Suk organization: the Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea (Ryu) – sequence: 7 givenname: Ilias P surname: Nikas fullname: Nikas, Ilias P organization: Medical School, University of Cyprus, Nicosia, Cyprus (Nikas) |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38871358$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kMtuFDEQRa0IRB7wAdkgL9l08KPdD3ajzlNKBEpmP6pxl2eMuu3B5Qb1t_FzdEKyqkXde6p0Ttm7EAMydi7FhWlM8xXSAS6UULoQphLF4-qInUhT6kLJyhyzU6KfQohWKfmBHeumqaU2zQn7u94jv_SwC5Gyt3xl7ZTAzjw63g0w9T4UJb8bxylEu8fRU04z92HpOIcJQ_aQfdjxB8xAGZ4ZHSTrQxyB-HWK47KimPc4eBj4jxQtEiE9M54wxYn4lXMT-Rh4N-c4xN38ja_400wZxxfeI_72-IdD6F-uFBBgmMnTR_bewUD46XWesfX11bq7Le6_39x1q_vi0LZQYCWFaUEKEHWl-rLRopVgeyfKsjZG17Ktamlqt1USpKtbB7ZUdqnZrdGN1Gfsy3_sIcVfE1LeLBYsDgMEXN7faFE1tVlsqiX6-TU6bUfsN4fkR0jz5s23_gf4BIYu |
ContentType | Journal Article |
Copyright | 2024 College of American Pathologists. |
Copyright_xml | – notice: 2024 College of American Pathologists. |
DBID | NPM 7X8 |
DOI | 10.5858/arpa.2023-0560-RA |
DatabaseName | PubMed MEDLINE - Academic |
DatabaseTitle | PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1543-2165 |
ExternalDocumentID | 38871358 |
Genre | Journal Article |
GroupedDBID | --- -~X .55 04C 23N 2WC 36B 3V. 53G 5GY 5RE 6PF 7RV 7X7 88E 88I 8AF 8AO 8C1 8FE 8FH 8FI 8FJ 8R4 8R5 AAWTL ABCQX ABDBF ABOCM ABUWG ACGFO ACGOD ACPRK ADBBV ADOJX AENEX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AZQEC B0M BAWUL BBNVY BENPR BHPHI BKEYQ BKOMP BMSDO BPHCQ BVXVI CCPQU DIK DWQXO E3Z EAP EAS EBC EBD EBS ECF ECT ECV EHN EIHBH EJD EMB EMK EMOBN ENC EPL EPT ESX F5P FAC FAL FJD FJW FRP FYUFA GNUQQ GX1 HCIFZ HMCUK IAO IEA IHR IHW INH INR IOF ITC L7B LK8 M1P M2P M2Q M7P NAPCQ NPM OK1 P2P PCD PQQKQ PROAC PSQYO PV9 Q2X Q~Q RWL RXW RZL SV3 TAE TAF TR2 TUS TWZ UDS UKHRP W2D WH7 WQ9 X6Y X7M Y3D ~8M 7X8 |
ID | FETCH-LOGICAL-p99a-e61059a10a0762d483091acdf044755371967157fb21a1f79fac42ce61cb53813 |
IngestDate | Sat Aug 17 04:47:22 EDT 2024 Wed Oct 23 09:55:05 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | 2024 College of American Pathologists. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p99a-e61059a10a0762d483091acdf044755371967157fb21a1f79fac42ce61cb53813 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doi.org/10.5858/arpa.2023-0560-ra |
PMID | 38871358 |
PQID | 3068753582 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_3068753582 pubmed_primary_38871358 |
PublicationCentury | 2000 |
PublicationDate | 2024-Jun-14 20240614 |
PublicationDateYYYYMMDD | 2024-06-14 |
PublicationDate_xml | – month: 06 year: 2024 text: 2024-Jun-14 day: 14 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Archives of pathology & laboratory medicine (1976) |
PublicationTitleAlternate | Arch Pathol Lab Med |
PublicationYear | 2024 |
SSID | ssj0009221 |
Score | 2.312844 |
Snippet | Distinguishing metastatic carcinomas from mesotheliomas or reactive mesothelial cells in pleural, peritoneal, and pericardial effusions is a common diagnostic... CONTEXT.—Distinguishing metastatic carcinomas from mesotheliomas or reactive mesothelial cells in pleural, peritoneal, and pericardial effusions is a common... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
Title | The Diagnostic Accuracy of Claudin-4 Immunochemistry in Differentiating Metastatic Carcinomas From Mesothelial Processes in Serous Effusion Cytology: A Systematic Review and Meta-analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38871358 https://www.proquest.com/docview/3068753582/abstract/ |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2lrYR4QdzbAtEg8Ra5xNe1eQtpqlKagFpXypu166zbCNeJUhsEH8RP8HPMeO3YBJAKL1ZkyxvFc7Jz8ZkzjL0SpgpsyT3DjWWMCYqShj_j3CBX69uJI52yUXg88Y4vnJOpO-10vrdYS0UuD-Jvf-wr-R-r4jm0K3XJ_oNl14viCfyM9sUjWhiPt7bxoebKke7qII6LFY1vJ4pFKgp0S4bTe0cdIDQXSw92owLHYTUVJSe7ZJe9scoFdRbhGkOaLZQRaQhj2sU1XrqhHq2UCutVU0FJ4aJNhtizoyQpqODWG37NdeNL2ep-3ghEV9L9JaEDv8cQlQxKOyxu69_SjGQtDEWorEBKTICaBlBqS2F80ypivE_VPBN6AvdYaOa0niOmK_IniyuBDuWmqdwOvuA297msE5_PszgV81XzL7kSnzTZ81Klol0XsRzib-l-1ANV7eWObVimHkWx6SkwS6LuB7FakviURRxGr2-crSVXG1XuyYfo6OL0NApH03CL7Vg8cIk66g8bKlFgWaZ-Y07Lvv5t0b9nL2UUE95n96r0AwYaSw9YR2UP2Z1x9WQfsR8IKWggBTWkYJHAGlKwASmYZ7ABKWggBQ2kgCAFLUjBGlK0hoYU1JCCGlJvYAANoEADChBQ8AugHrPwaBQOj41qvoexDAJhKI9ie2H2RR898szxbYxdRTxL-iRC6docnQM3XZ5IyxRmwoNExI4V422xRDdt2k_YdrbI1C4DiqM96UlHonvh_VkgpZuIABdypVSut8de1gaI8MnQOzGRKfxJEWbMlLG7vrXHnmrLREut8xLZ6IBNvLR_i7ufsbsNCJ-z7XxVqBcYruayy7b4lHdLxHTZztvR5OPZT0wjos8 |
link.rule.ids | 315,786,790,27955,27956,31753,33300,33778 |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Diagnostic+Accuracy+of+Claudin-4+Immunochemistry+in+Differentiating+Metastatic+Carcinomas+From+Mesothelial+Processes+in+Serous+Effusion+Cytology%3A+A+Systematic+Review+and+Meta-analysis&rft.jtitle=Archives+of+pathology+%26+laboratory+medicine+%281976%29&rft.au=Kleinaki%2C+Maria&rft.au=Vey%2C+Johannes+A&rft.au=Awounvo%2C+Sinclair&rft.au=Ishak%2C+Angela&rft.date=2024-06-14&rft.eissn=1543-2165&rft_id=info:doi/10.5858%2Farpa.2023-0560-RA&rft.externalDBID=NO_FULL_TEXT |